Assessment of biochemical and sonographic marker to predict the risk for developing
preeclampsia Among biochemical markers are serum level of Placental Protein 13 (PP13) and
Placenta Growth factor (PIGF). For sonographic marker Doppler pulsatility Index of the blood
flow through the uterine maternal arteries is assessed.
PP13 is produced by the placenta and released to the maternal blood circulation. It has been
shown to be an effective serum marker for early onset preeclampsia (Nicolaides KH et al.,
2005). The purpose of this study is to combined the assessment of the biochemical markers
with Doppler in the first and the second trimester to provide a comprehensive evaluation of
various methods for sequential and combined analysis to assess the risk for developing
preeclampsia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ben-Gurion University of the Negev
Collaborators:
Diagnostic Technologies Ltd. Medical University of Graz Perkin Elmer Inc.